ETS variant gene 6 (ETV6)/translocation, ETS, leukemia (TEL)-involving chromosomal translocations are frequently observed in various hematologic neoplasms. We describe here a novel ETV6-involving translocation, t(12;13)(p13;q14), found in the case of acute lymphoblastic leukemia, in which ETV6 fused with a previously unknown gene, named Twelve-thirteen Translocation Leukemia gene (TTL), at 13q14. TTL was weakly but ubiquitously expressed in normal human tissues as detected by reverse transcribed-PCR. Three TTL splicing forms were identified, TTL-T from a human testis cDNA library, with an open-reading frame of 402 bp encoding 133 amino acids (aa), and TTL-B1 and -B2 from a human brain cDNA library. These proteins have no homology to known proteins. In leukemic cells from the patient, both reciprocal fusion transcripts, ETV6/TTL and TTL/ETV6, were expressed. The predominant fusion transcript, TTL/ETV6-1, encodes a predicted 530 aa fusion protein containing 89 aa of the N-terminal TTL fusing to the helix-loop-helix domain and ETS-binding domain of ETV6. Although the function of TTL is yet to be elucidated, our findings will provide another insight into the molecular pathogenesis of leukemia having ETV6-involving translocations.
Introduction
Leukemia-associated chromosomal translocations frequently result in the creation of aberrant fusion genes, which play a pivotal role in leukemogenesis. 1 A number of chimeric genes have been cloned and characterized from nonrandom translocations, including AML1/MTG8 in t(8;21)(q22;q22), 2 PML/RARA in t(15;17)(q22,q21), 3 and ETV6/PDGFRb in t(5;12)(q33;p13). 4 ETV6 (ETS variant gene 6), also known as TEL (translocation, ETS, leukemia), is a member of the Ets family of transcription factors and is characterized by a C-terminal Ets domain responsible for specific DNA-binding activities and an N-terminal helix-loop-helix (HLH) oligomerization domain that is suggested to play a role in the protein-protein interaction with Ets factors to modulate transcriptional activity. ETV6 is mapped to chromosome 12p13 and was originally identified as a gene that is fused to PDGFRb gene in t(5;12)(q33;p13), one of the recurring chromosomal translocations found in chronic myelomonocytic leukemia (CMML). 4 Subsequently, a growing number of genes, including ABL, 5 JAK2, 6, 7 HLXB9, 19 and PAX5, 20 have been identified as fusion partners of ETV6 in more than 40 different chromosomal translocations in a broad spectrum of hematopoietic neoplasms. In normal hematopoietic cells, ETV6 appears to act as a transcriptional repressor and is essential for the definitive hematopoiesis. 21, 22 However, several implications have been advanced as to the significance of functional modifications of ETV6 and translocation partners in leukemogenesis. Therefore, the identification and characterization of new fusion partners of ETV6 may help to further understand the critical role of ETV6 in the development of leukemias with these ETV6-involving translocations.
t(12;13) is a rare, but recurring chromosome translocation described in a wide spectrum of leukemias including acute lymphoblastic leukemia (ALL), [23] [24] [25] [26] [27] AML, [28] [29] [30] [31] [32] [33] [34] CML, 35 CLL, and MDS. 30 A literature search revealed at least 35 or more cases with t(12;13) harboring breakpoints cytogenetically scattered from 12p11 to 12p13 and from 13q11 to 13q34. With regard to the breakpoints on 13q, there seem to exist at least three distinct types of translocations: t(12;13)(p11-13;q12), t(12;13) (p11-13;q14), and t(12;13)(p11-13;q34). Among them, 13 cases had a breakpoint at 12p13 and 13q14, including seven cases of ALL, four cases of AML, one CMML, and one MDS. In ALL, five had a pre-B-lineage phenotype and six were pediatric ALL. The molecular nature of these t(12;13)(p13;q14) translocations, however, has not been clarified to date.
We report here a molecular delineation of a case of t(12;13)(p13;q14) observed in an adult pre-B ALL, in which ETV6 is rearranged with a novel gene, TTL, on 13q14, and both ETV6/TTL and TTL/ETV6 fusion messages are transcribed. Our finding might provide important clues in understanding the molecular mechanism of the t(12;13)(p13;q14) translocation in leukemogenesis.
Materials and methods

Patients
The patient was a 46-year-old man, diagnosed as ALL in 1995. Cytogenetic analysis of his blasts showed a karyotype of 46,XY,add(6)(q15),t(12;13)(p13;q14),add(22)(q11). Once he attained a complete remission, but was relapsed thereafter and died of the refractory disease 4 years after the diagnosis. The immunophenotype of his blasts was CD10(+/À), CD19(+), CD20(À), CD33(+), and CD34(+). The sample used in this analysis was obtained with the informed consent.
Fluorescent in situ hybridization (FISH)
Since this translocation involves 12p13, which is the locus for ETV6, we investigated the potential involvement of ETV6 gene by FISH experiments with a panel of cosmid probes containing different exons of ETV6. The cosmids were kindly provided by Dr Peter Marynen (University of Leuven, Belgium). The order and the relative locations of these cosmids are depicted in Figure 1a . FISH analyses on chromosome 12 were performed according to the standard procedures. 36, 37 Briefly, the probes were labeled by nick translation using biotin-16-dUTP (Boehringer, Mannheim, Germany). After overnight hybridization and posthybridization washes, the hybridized probes were detected via an avidin-fluorescein isothiocyanate (Boehringer, Mannheim, Germany). For identification, chromosomes were counter stained with 4,6-diamidino-2-phenylinodole. The presence or absence of the FISH signals was scored on an average of three to six abnormal metaphase cells per probe.
Southern blotting
In all, 10 mg of high-molecular weight DNA were extracted from blood and bone marrow cells of this patient by standard procedure, digested to completion with either HindIII or EcoRI restriction endonucleases and subjected to Southern blot analysis as described. 38, 39 According to the restriction enzyme map, a series of genomic probes covering the region from exons 1 to 3 of ETV6 gene were prepared by genomic PCR and labeled with 32 P-deoxycytoxine triphosphate (dCTP) by random priming. PCR primers of 95H4-F1 and 95H4-R1 were used for making probe of 95H4-F.
Rapid amplification of cDNA end (RACE)
We adopted the RACE method to identify the fusion partners of ETV6 in t(12;13)(p13;q14). Assuming both reciprocal fusion transcripts involving ETV6, 3 0 RACE was used for obtaining the 3 0 fusion fragment with ETV6 exon 1, and 5 0 RACE for the 5 0 fusion fragment. Total RNA was extracted from a cryopreserved leukemic sample of this patient as described previously. 38 For 3 0 RACE, the primer R2N6 was used for reverse transcription. Nested 3 0 RACE-PCR was performed using primers specific for ETV6 exon 1, ETV6-F1a and ETV6-F1b, in combination with primers N6R1 and N6R2, respectively. 7, 16 For 5 0 RACE, the firststrand cDNA was tailed with dCTP, followed by nested PCR with primers specific for ETV6 exon 3, ETV6-R3a and ETV6-R3b, 16 in combination with primers of 5 0 -adaptor-UAP-1 and 5 0 -adaptor-UAP-2, respectively. The nucleotide sequences of primers R2N6, N6R1, N6R2, ETV6-F1a, ETV6-F1b, ETV6-R3a, and ETV6-R3b are the same as described by Peeters et al 7 and Cools et al. 16 The thermal cycling profile was as follows: 941C for 2 min followed by 35 cycles of 941C for 45 s, 601C for 45 s, 721C for 90 s, and a final extension at 721C for 10 min. The PCR products were subcloned into the TA vector (Invitrogen, Tokyo, Japan) and the positive colonies were screened by colony hybridization using the standard protocols. We isolated clones positive for the ETV6 exon 1 but negative for ETV6 exon 2 in the 3 0 RACE experiment, and those positive for ETV6 exon 2 and 
A novel
0 RACE experiment were selected. All the selected clones were sequenced using fluorescently labeled dideoxy terminators on the 377 Applied Bisystems automated sequencer (Applied Biosystems, Urayasu, Japan).
cDNA library screening
Human testis and brain cDNA libraries in lambda gt11 (10 9 pfu/ml) (kindly provided by Dr Shuntaro Ikawa, Tohoku University, Japan) were screened for cDNAs of the fusion partner with the fragments identified by 3 0 RACE experiments as probes. The probes were labeled with 32 P-dCTP by random priming. Positive clones were subcloned into pBluescript-KS(À) and sequenced.
Radiation hybrid mapping
The GeneBridge 4 Radiation Hybrid Panel (Research Genetics, Huntsville, AL, USA) was used for chromosome mapping. A series of PCRs were carried out for this panel by using primers RHM-F and RHM-R, which are specific for the fragments identified by 3 0 RACE experiments. The PCR cycle condition was as follows: one initial cycle of 2-min denaturation at 941C, followed by 45 cycles of 30-s denaturation at 941C, 30-s annealing at 601C and 1-min extension at 721C, and a final cycle extension of 10-min at 721C. The PCR results from the radiation mapping vectors were formatted according to the manufacturer's instructions and were analyzed using the server at the Stanford Human Genome Center (http:// www-shgc.stanford.edu) to search the STS markers on the screening panel.
Reverse transcribed reaction-PCR (RT-PCR)
In all, 5 mg of the total RNA from leukemic cells of the patient were RT with 2 U of Moloney murine leukemia virus reverse transcriptase (MMLV-RT, Stratagene, USA) using a random hexamer or an oligo-dT primer (Ro-Ri-oligo-dT).
14 One tenth of the synthesized cDNA was directed to PCR analysis. For amplification of ETV6/TTL transcripts, primers ETV6-F1 and TTL-R1 were used for the first round, and ETV6-F2 and TTL-R2 for the second round. The first and second round primers for TTL/ETV6 were TTL-F1 and ETV6-R1, and TTL-F2 and ETV6-R2, respectively ( Figure 2 ). For amplification of TTL messages, we used TTL-F3 and TTL-R3 for the first round PCR, and TTL-F4 and TTL-R4 for the second round. For detection of full-length ETV6 expression from leukemic cells of the patient, primers ETV6-F1 and ETV6-R3 were used in the RT-PCR. The PCR conditions were the same as described above.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed using a LightCycler-FastStart DNA Master SYBR Green I kit and instrument (Roche Diagnostics, Mannheim, Germany). For the construction of standard curves, ETV6-and TTL/ETV6-containing plasmids, pME18s-ETV6 and pME18s-TTL/ETV6, 40 were used with serial dilutions according to the manufacturer's instructions and the concentration of MgCl 2 was adjusted to 2 mM. The RT cDNA samples from the patient were prepared as described above. PCR primers for ETV6 amplification are ETV6-F3 and ETV6-R4, and those for TTL/ETV6 are TTL-F4 and ETV6-R2. PCR conditions are as follows: initial denaturation at 951C for 10 min, followed by 30 cycles at 951C for 15 s, 601C for 5 s and 721C for 8 s. Data were calculated by using LightCyclert analysis software provided by the LightCycler apparatus. The specificity of the PCR reactions was also verified by ethidium bromide staining on 2% agarose gels.
Primers
Primers used in PCRs were listed in the Table 1 .
Results
Identification of the breakpoint on chromosome 12
From the G-banding analysis, the breakpoint on chromosome 12 was expected to be within ETV6 gene. To test this, we performed FISH experiments using several probes from the ETV6 locus ( Figure 1a ). Hybridization signals from cosmids 179A6 and 50F4, which contain exons 1A and 2 of ETV6 gene, respectively, were found on der(13) as well as the apparently normal chromosome 12 (data not shown), whereas signals from cosmids 2G8 ( Figure 1b ) and 163E7 (data not shown) containing exons 1B, 3-5 , respectively, were on der(12) but not on der(13), indicating the breakpoint on 12p13 to be within ETV6 gene, around exon 2. To further define the breakpoint on 12p13, Southern blot was performed with a series of genomic probes covering the range of introns 1 and 2 of ETV6 gene. With a genomic probe located in the intron 1 of ETV6 gene, tumorspecific rearrangement bands were identified (Figure 1c and d) . According to the restriction map of ETV6 and the sequence analysis of the locus, the breakpoint on 12p13 was finally localized within a 5.6 kb HindIII/EcoRI fragment, which is between ETV6 exons 1 and 2, (Figure 1d ), indicating a possibility that ETV6 may participate in the genetic aberration that would result in the generation of a fusion transcript involving the other yet undefined gene on 13q14.
Identification of the fusion partner of ETV6 with RACE-PCR
To identify the possible fusion partner of ETV6, we tried 3 0 as well as 5 0 RACE-PCRs for leukemic samples from the patient. Although the 5 0 RACE PCR failed to amplify possible fusion messages, 3 0 RACE-PCR products were successfully obtained, subcloned into plasmids, and screened by colony hybridization, in which colonies positive for ETV6 exon 1 and negative for ETV6 exon 2 were isolated and subjected to the sequencing analysis. All the analyzed clones contain a still unknown sequence with a consensus 450 bp in length (F450 fragment in Figure 2a ) immediately after the end of the ETV6 exon 1. As shown below, the latter unknown sequence was revealed to be a part of a novel gene, designated as TTL for Twelve-thirteen Translocation Leukemia gene. The chimeric transcript comprises the ETV6 exon 1 in-framely fusing to the F450 fragment, within which a stop codon appears 60 bp downstream from the fusion point. To further confirm the localization of the F450 fragment, we performed radiation hybrid mapping. The data were transmitted and analyzed by the Stanford Human Genome Center and indicated that this novel sequence was located on the long arm of chromosome 13, between CHLC.GATA6B07 and WI-13180.
Identification of full-length cDNAs for a novel gene, TTL Since the unknown 450 bp sequence from the putative novel gene, TTL, has no homology to known genes, we first examined its expression in human tissues. Northern blot analysis using a human RNA panel failed to detect any TTL transcripts.
However, using nested RT-PCR, we could find almost ubiquitous TTL expression in human tissues, including lung, liver, thymus, and bone marrow (Figure 3a) . The TTL message could be detected on the first round of the nested PCR in brain and testis, suggesting relatively higher expression of TTL in these tissues. By screening human testis and brain cDNA libraries with the 450 bp novel sequence (F450 fragment) as a probe and employing 5 0 and 3 0 RACE and RT-PCR, we identified three splicing forms of TTL, TTL-T, TTL-B1 and -B2 (Figures 2b and 4 . Accession nos. AY116214, AY116215, and AY116216, respectively.) The sequences of these clones were further used to search GeneBank for genomic clones corresponding to the TTL locus, and we identified two BAC clones for the TTL locus, namely, clone RP11-350A18 and clone RP11-172E9 (Figure 2a) . By comparing cDNA sequences with deposited genomic sequences of these clones, we determined the genomic organization of TTL exons depicted in Figure 2 .
TTL-T, isolated from human testis library, is 2090 bp in length with a polyA tail and composed of TTL exons 1-8. The longest open-reading frame (ORF) of TTL-T, that follows the Kozac's rule, harbors exons 4, 5, and a part of exon 6, encoding 133 amino acids (aa) which so far has no homology to known proteins in GeneBank (Figures 2a and 4a) .
TTL-B1 on the other hand, was originally isolated from the human brain library as a fragment containing part of exons 5 and 9. By 3 0 RACE in combination with a series of PCR experiments (data not shown), we determined its polyA end that appeared at the terminal of exon 9 consisting of 3183 bp. In the following nested RT-PCR on human testis RNA using outer (TTL-382-F, TTL-R3) and inner (TTL-411-F, TTL-R4) primary sets (Figure 2b ), we identified a transcript that contained TTL exons 4, 5, and a 5 0 sequence of exon 9. Thus, the expected TTL-B1 splicing form consists of at least 3450 bp and contains an ORF, which starts from the same start codon as TTL-T but differentially terminates at the 20th codon (TGA) of exon 9 (Figures 2b and 4b) .
Finally, we also found the other form of TTL, TTL-B2, in which the exon 8a sequence is inserted between exons 5 and 9. Expression of this form of transcript was detected by RT-PCR in a wide variety of tissues and cell types, including bone marrow, thymus, spleen, and liver ( Figure 3a , the large band). Although we could not isolate the full length of TTL-B2, it may well correspond to the TTL-B1 form with an exception that it has the insertion of exon 8a between exons 5 and 9 (Figures 2b and 4b) . The putative TTL-B2 has 3588 bp and its ORF is supposed to share the same ATG codon with TTL-B1 and TTL-T, but stopped immediately within exon 8a (Figures 2b and 4b) . Thus, the predicted amino acids from the three splicing form share the first 89 aa encoded by a part of exons 4 and 5, but have different carboxyl termini depending on the different splicing.
Expressions of TTL-B1, TTL-B2 (Figure 3a) , and TTL-T (data not shown) were demonstrated by nested RT-PCR in a variety of normal tissues (Figure 3a) as well as leukemia/lymphoma cell lines, including Raji (B-malignant lymphoma), HPB-NULL (B-ALL), BALM1 (B-ALL), KCL22 (B-CML), MT1 (T-ATL), Peer (T-ALL), ATL35 (T-ATL), and Jurkat (T-ALL) (data not shown). Table 1 Primers used for PCR amplifications
Figure 3
Expression of TTL and TTL fusion transcripts. (a) RT-PCR analysis of TTL expression in normal human tissues. Two specific bands were detected according to the presence or absence of the exon 8a in the transcripts as revealed by sequencing of the PCR products. Primers, TTL-F3 and TTL-R3, were for the first round PCR, and TTL-F4 and TTL-R4 for the second round PCR. GAPDH positive controls are shown below. (b) Detection of TTL/ETV6 as well as ETV6/TTL fusion messages by RT-PCR in the patient's leukemic sample. Two alternative forms of TTL/ETV6 (with primers TTL-F1 and ETV6-R1 for the first round PCR and TTL-F2 and ETV6-R2 for the second round) and a single ETV6/TTL fusion transcript (with primers ETV6-F1 and TTL-R1, and ETV6-F2 and TTL-R2 for the first and second round PCR, respectively) are specifically detected in leukemic cells having t(12;13)(p13;q14). (c) Detection of ETV6 message with RT-PCR. With primers within ETV6 exon 1 (ETV6-F1 primer) and exon 8, (ETV6-R3 primer) the predicted product is 1516 bp in length.
Detection of the TTL/ETV6 and ETV6/TTL fusion transcripts with nested RT-PCR
Both reciprocal fusion transcripts, TTL/ETV6 and ETV6/TTL, were detected in the primary tumor sample by nested RT-PCR (Figure 3b) . To identify the TTL/ETV6 fusion, nested RT-PCR analysis on patient materials was performed using forward primers in TTL exon 5, and reverse primers in ETV6 exon 3. As shown in Figure 3b , two bands were specifically amplified from the sample of the patient. Sequence analysis disclosed that the smaller but major band (TTL/ETV6-1) corresponded to the inframe fusion of part of the exon 5 of TTL to the 5 0 end of ETV6 exon 2, while the larger one (TTL/ETV6-2) was an out-of-frame fusion of the part of exons 5 and 8a of TTL to the ETV6 exon 2 A (Figure 2b ). The ORF of the latter fusion transcript is prematurely terminated in the stop codon within exon 8a of TTL before it fuses to ETV6 exons. The reciprocal chimeric transcript of ETV6 exon 1 and TTL (ETV6/TTL) could also be detected by RT-PCR, in which ETV6 exon 1 was fused to the 5 0 end of the exon 9 of TTL-B (Figure 2b) . We evaluated the integrity of the remaining ETV6 locus by FISH analysis, in which all the signals of the four cosmid probes were normally detected on the remaining, apparently normal chromosome 12, indicating that the other ETV6 locus is grossly intact with no large deletions. To confirm the expression of ETV6 from the intact allele, we performed RT-PCR analysis for the patient's leukemic sample using primers located within ETV6 exons 1 and 8. As shown in Figure 3c , the leukemic sample clearly showed ETV6 expression. Sequencing analysis of the RT-PCR product confirmed that there were no mutations in the RT product.
Analysis of mRNA expression levels of ETV6 and TTL/ETV6
We measured expression levels of ETV6 and TTL/ETV6 transcripts in the leukemic cells of the patient by the quantitative real-time RT-PCR analysis using LightCyclert. It demonstrated that the level of TTL/ETV6 transcript was 40-fold lower than that of ETV6 transcript (Figure 5a ). Agarose gel analysis showed RT-PCR bands of the correct size (Figure 5b ). Discussion t(12;13)(p13;q14) is a recurring reciprocal chromosome translocation found in ALL as well as in AML, CML, CLL, and MDS. From the cytogenetic analysis, it is thought to be cytogenetically distinct from t(12;13)(p13;q12), in which ETV6 is shown to be combined with CDX2.
14 In fact, the ETV6/CDX2 message was not detected by RT-PCR in our case (data not shown). Rather we have revealed that a novel gene, TTL, at 13q14 was rearranged with ETV6 at 12p13, resulting in reciprocal fusion transcripts, TTL/ETV6 and ETV6/TTL, in a case with t(12;13)(p13;q14). However, it is still unclear whether all the cases described as t(12;13)(p13;q14) have the same molecular abnormality, since they have been reported to involve leukemias of apparently different lineages.
The involvement of the ETV6 gene in leukemia-associated translocations is notable for its wide variety of fusion partners with different breakpoints in various subtypes of leukemias. 41 This promiscuous feature of ETV6-involving translocations and their breakpoint variations apparently make it difficult to give a simplified and straightforward explanation for the leukemogenic mechanism of ETV6-involving translocations. Rather, it seems to involve different modalities according to the context of the type of translocations.
Clearly, the functional modification of the fusion partners is critically important in some cases. For examples, in ETV6/ PDGFRb and other fusions involving ETV6 and tyrosine kinases, the HLH domain of ETV6 functions as a homodimerization motif that is necessary for the constitutive activation of their Cterminal tyrosine kinases. 42 In t(12;21), the ETV6/AML1 inhibits the function of AML1 in a dominant-negative fashion. 43 In other cases, in contrast, there are no known functional domains of ETV6 or the partner proteins found in the fusion products (such as ETV6/STL 15 12 ). In the latter examples, the promoter of ETV6 might drive ectopic expression of the transcription factors, CDX2 and EVI1.
In the current translocation, both possible reciprocal fusion transcripts, TTL/ETV6 and ETV6/TTL, were expressed in the tumor cells, which is also the case with MN1/ETV6 and ETV6/ MN1 in t(12;22)(p13;q11), 13 ACS2/ETV6 and ETV6/ACS in t(5;12)(q31;p13), 18 and STL/ETV6 and ETV6/STL in t(6;12)(q23;p13). 15 With regard to ETV6/TTL fusion transcript, the 3 0 TTL sequence introduced an in-frame stop codon 60 bp after the end of ETV6 exon 1, resulting in only a potential 31 aa, and it could be hardly expected that this extremely short fusion protein would have any functional roles. The other transcript, TTL/ETV6, has two splicing forms, the predominant TTL/ETV6-1 and less abundant TTL/ETV6-2. The predominant TTL/ETV6-1 transcript was a direct in-frame fusion between TTL exon 5 and ETV6 exon 2, in which the first 11 aa of ETV6 are replaced by 89 aa from the potential ORF of TTL. Since the predicted 530-aa fusion protein consists mostly of ETV6 with both HLH and ETS domains being preserved, it might potentially have some transcriptional activities, most likely to modify ETV6 function. However, in quantitative estimation using real-time PCR, the expression of TTL/ETV6 was almost negligible compared with the remaining expression of ETV6, and we could not attribute any functional significance to this fusion protein.
In view of no functional implications in the resulting fusion proteins, the pathological significance of this translocation would be better explained by the hypothesis of loss of function of ETV6 and/or TTL. It has been much discussed that loss of, and even haplo-insufficiency of ETV6 function might be important for leukemogenesis, based on the observation that the second ETV6 allele is deleted in some ETV6 translocations, especially in more than 90% of cases associated with t (12;21) . 44, 45 In vitro 7) and TTL/ETV6 (lanes [8] [9] [10] [11] [12] [13] [14] . Two plasmid constructs, pME18s/ETV6 (lanes 1-5) and pME18s-TTL/ETV6 (lanes 8-12), were used as standards with 10-fold serial dilutions starting from 40 ng/tube and 4 mg/tube for quantification of ETV6 and TTL/ETV6 messages in patient's samples, respectively. Lanes 6 and 13 are negative controls. 200 ng (lanes 7 and 14) of cDNA from the leukemic sample were subjected to the real-time PCR assay.
A novel ETV6 fusion partner Y Qiao et al experiments, in which expression of ETV6 inhibited the growth of Ras-transformed cells in soft agar, also support that ETV6 could function as a tumor suppressor. 46 According to this hypothesis, one ETV6 allele was disrupted by the t(12;13)(p13;q14) in our cases. It could not be clearly determined whether the other allele of ETV6 was also inactivated in the patient's sample, because of the unavoidable contamination of normal cells. However, no large deletions were detected in the other allele on FISH, and the expression of normal ETV6 could be detected in the tumor sample with more than 90% of leukemic cells. Whether even haploid deficit of ETV6 gene could cause leukemia is still under dispute, although haplo-insufficiency of RUNX1, RUNX-3, and p27 (KIP1) genes was shown to produce phenotypic alterations or even to develop cancers in genetically engineered mice. [47] [48] [49] On the other hand, we know little about TTL except that it is expressed ubiquitously at low levels. It has no known similarity to other proteins. We failed to identify the mouse TTL homologue in spite of an extensive blast search in GeneBank, although the nearby gene of TTL, FOXO1A, has its murine counterpart on the mouse chromosome 3. TTL was mapped to 13q14, one of the hot spots of deletion in CLL, but it is totally unclear whether disruption of TTL might contribute to leukemogenesis for the time being.
Finally, there might be a possibility that the translocation could affect expression of the surrounding genes of ETV6 or TTL. 50 In this context, p27 and FOXO1A are among the candidates for such genes that reside near ETV6 on 12p13, and TTL on 13q14, respectively, 51, 52 and we examined their expression in primary tumor sample. By RT-PCR, however, neither of the two genes showed abnormal expression levels in the sample of the patient compared to normal human lymphocytes (data not shown).
In conclusion, we have reported a novel fusion partner of ETV6 gene, TTL, from the recurring translocation t(12;13)(p13;q14), in which both reciprocal fusion messages, TTL/ETV6 and ETV6/TTL, were transcribed. It is still unclear whether TTL/ETV6 and ETV6/TTL act as aberrant transcription factors, or merely bystander products of ETV6 and/or TTL disruptions through the translocation. Further investigation will be required to unearth the underlying molecular mechanism of these ETV6-containing fusion genes as well as the function of TTL gene itself, with relation to leukemogenesis.
